Brasada Capital Management LP boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 39.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,142 shares of the medical equipment provider’s stock after purchasing an additional 2,283 shares during the period. Brasada Capital Management LP’s holdings in Hologic were worth $304,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Hologic during the 1st quarter worth $146,000. Synovus Financial Corp bought a new stake in shares of Hologic in the 1st quarter valued at about $164,000. IBM Retirement Fund bought a new stake in shares of Hologic in the 1st quarter valued at about $227,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Hologic in the 4th quarter valued at about $235,000. Finally, United Capital Financial Advisers LLC grew its stake in Hologic by 34.4% in the 1st quarter. United Capital Financial Advisers LLC now owns 6,395 shares of the medical equipment provider’s stock valued at $239,000 after buying an additional 1,638 shares during the last quarter. Hedge funds and other institutional investors own 93.34% of the company’s stock.
In related news, insider Peter J. Valenti III sold 10,107 shares of Hologic stock in a transaction dated Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total value of $389,321.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of Hologic stock in a transaction dated Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the completion of the sale, the vice president now owns 13,825 shares of the company’s stock, valued at $553,000. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by company insiders.
Shares of Hologic opened at $39.75 on Friday, Marketbeat Ratings reports. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $45.82. The company has a market capitalization of $10.76 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 1.86 and a beta of 0.86. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 1.13.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business had revenue of $789.30 million during the quarter, compared to analyst estimates of $781.23 million. During the same period last year, the firm posted $0.50 EPS. The company’s revenue was up 10.3% on a year-over-year basis. analysts expect that Hologic, Inc. will post 2.23 EPS for the current fiscal year.
A number of research analysts have issued reports on HOLX shares. ValuEngine lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Thursday, May 3rd. BTIG Research reaffirmed a “buy” rating and set a $44.00 price target on shares of Hologic in a research note on Sunday, May 6th. Canaccord Genuity downgraded shares of Hologic from a “buy” rating to a “hold” rating and dropped their price target for the company from $48.00 to $39.00 in a research note on Thursday, May 3rd. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Finally, Barclays reduced their price target on shares of Hologic from $54.00 to $50.00 and set an “overweight” rating for the company in a report on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.87.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.